PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Mechanism of action
Clinical evidence
Improved hypermenorrhea and dysmenorrhea in >90% of cases, with shrinking of myomas in approximately 60% of cases [PMID:1471615]
Improved hot flashes, possibly by decreasing plasma CGRP levels [PMID:12818465]; significantly increased blood flow in extremities compared to hormone replacement therapy [PMID:15974485]
When combined with Dai-ken-chu-to, it significantly reduced time to flatus and time to tolerance of regular diet, and shortened postoperative hospitalization [PMID:15783004]
Decreased specific antiendometrial IgM antibody titers and kept a patient symptom-free for over 7 months [PMID:9834624]
Significantly reduced the surface area of thoracic aorta with visible plaque in cholesterol-fed rabbits [PMID:10353155, PMID:15684487]
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 34704418 (2021) — Clinical and genetic characteristics of Keishi-Bukuryo-Gan syndrome: an analysis of 5 cases. · Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
- 2.PMID: 15070171 (2004) — Effects of Keishi-bukuryo-gan on vascular function and hemorheological factors in spontaneously diabetic (WBN/kob) rats. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 3.PMID: 10353155 (1999) — Keishi-bukuryo-gan prevents the progression of atherosclerosis in cholesterol-fed rabbit. · Phytotherapy research : PTR
- 4.PMID: 1471615 (1992) — Pharmacotherapeutic effects of kuei-chih-fu-ling-wan (keishi-bukuryo-gan) on human uterine myomas. · The American journal of Chinese medicine
- 5.PMID: 36754204